AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06477523
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).
Trial: NCT05103683
Drug: TORL-1-23
RxNorm normalized name: TORL-2-307
DrugBank: TORL-2-307 (DB18376)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antibody drug conjugate (ADC)
Trial: NCT03962465
Drug: Inotuzumab ozogamicin
RxNorm normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: By IV, given on days 12 and 19 Inotuzumab ozogamicin is approved as a single-agent in this population (patients with B-ALL) but adding it to these drug combinations has not been tested in humans
Trial: NCT03962465
Drug: Prednisone Pill
RxNorm normalized name: prednisone Pill
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Taken daily days 1-28 by mouth
Trial: NCT03962465
Drug: Daunorubicin
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: By IV, given on days 1, 8, 15, and 22
Trial: NCT03962465
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: By IV, given on days 1, 8, 15, and 22
Trial: NCT03962465
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intrathecal, administered on day 1 only
Trial: NCT04933903
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1mg/kg IV on day 1 (1 dose total)
Trial: NCT04933903
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 3mg/kg (to a maximum of 240mg) IV on days 1, 15, 29 (+/- 3 days) (3 doses total)
Trial: NCT03962465
Drug: Pegaspargase
RxNorm normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: By IV, given on day 4
Trial: NCT06333314
Drug: Dostarlimab
RxNorm normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Anti-PD-1 monoclonal antibody
Trial: NCT04710628
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab 200 mg will be administered to patients as 30-minute intravenous infusion (a window of -5 minutes and +10 minutes is permitted) every 3 weeks.
Trial: NCT04710628
Drug: Lenvatinib 10 mg
RxNorm normalized name: lenvatinib 10 MG
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenvatinib 20 mg (2 capsules of 10 mg) will be administered daily at the same time, with or without food. At the day 1 of each cycle, lenvatinib will be administered within 4 hours after finishing pembrolizumab (lenvatinib after pembrolizumab)
Trial: NCT04842747
Drug: VERU-111
RxNorm normalized name: Veru-111
DrugBank: Veru-111 (DB16462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in the VERU-111 treatment groups will receive standard of care, plus oral daily VERU-111 9mg for 21 days or until released from hospital.
Trial: NCT05501756
Drug: Alemtuzumab
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Alemtuzumab (Campath®) is a recombinant DNA-derived humanized monoclonal antibody directed against CD52. Alemtuzumab is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin. Neomycin is not detectable in the final product. Alemtuzumab is a sterile, clear, colorless, isotonic pH 6.8-7.4 solution for injection. Alemtuzumab is supplied in single-use clear glass ampules containing 30 mg of Alemtuzumab in 3 mL of solution. A single use vial of alemtuzumab contains 30 mg alemtuzumab, 8 mg sodium chloride, 1.44 mg dibasic sodium phosphate, 0.2 mg potassium chloride, 0.2 mg monobasic potassium phosphate, 0.1 mg polysorbate 80, and 0.0187 mg disodium edetate dihydrate.
Trial: NCT06200181
Drug: Olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given by PO
Trial: NCT04620239
Drug: padeliporfin VTP
RxNorm normalized name: Padeliporfin
DrugBank: Padeliporfin (DB15575)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: During treatment, placement at the target area of an optical light fiber, through the working channel of the ureteroscope. Intravenous administration of padeliporfin at the dose of 3.66 mg/kg infused over 10 minutes. Each target area will be illuminated for 10 minutes.
Trial: NCT04657406
Drug: Zofin
RxNorm normalized name: Zofin
DrugBank: Zofin (DB16519)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive standard of care plus 1 mL of Zofin on day 0, day 4 and day 8, containing 1-5 x 10\^11 particles/mL.
Trial: NCT05034029
Drug: Metformin hydrochloride sustained release tablets
RxNorm normalized name: metformin hydrochloride Extended Release Suspension
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral
Trial: NCT05478525
Drug: GLY-200
RxNorm normalized name: Gly
DrugBank: Glycine (DB00145)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5 g GLY-200 (1 x 0.5 g capsule) BID for 14 days (n=12)
Trial: NCT05478525
Drug: GLY-200
RxNorm normalized name: Gly
DrugBank: Glycine (DB00145)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.0 g GLY-200 (2 x 0.5 g capsules) BID for 14 days (n=12)
Trial: NCT05478525
Drug: GLY-200
RxNorm normalized name: Gly
DrugBank: Glycine (DB00145)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.0 g GLY-200 (4 x 0.5 g capsules) BID for 14 days (n=12)
Trial: NCT05355168
Drug: neoadjuvant chemoradiotherapy combined with Camrelizumab and Nimotuzumab followed by surgery
RxNorm normalized name: picodralazine and diuretics, combinations with psycholeptics
DrugBank: Nimotuzumab (DB06192)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: neoadjuvant chemoradiotherapy combined with Camrelizumab and Nimotuzumab followed by surgery
Trial: NCT06129409
Drug: NT-0796
RxNorm normalized name: NT-219
DrugBank: NT-219 (DB17490)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered capsules
Trial: NCT05537883
Drug: Liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients receiving the intervention will undergo Transversus Abdominis Plane (TAP) block with liposomal bupivacaine
Trial: NCT05537883
Drug: Bupivacaine Injection
RxNorm normalized name: bupivacaine Injection
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients receiving the intervention will undergo Transversus Abdominis Plane (TAP) block with plain bupivacaine
Trial: NCT05647252
Drug: Whole Body and nasal decolonization with octenidin (Octenisan Set)
RxNorm normalized name: octenidine
DrugBank: Octenidine (DB12624)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octenidin body lotion once a day during the five consecutive days preceding the elective orthopedic surgery, including for the hair.~Octenidin nasal creme 2-3 times a day in both nasal orifices during the same period
Trial: NCT03694158
Drug: Dupilumab
RxNorm normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: anti-IL4 receptor antagonist
Trial: NCT05800574
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin, 40mg/m2 (weekly for 7 weeks)
Trial: NCT05139472
Drug: Empagliflozin 10 MG
RxNorm normalized name: empagliflozin 10 MG
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daily Empagliflozin
Trial: NCT05516992
Drug: SB-01 For Injection
RxNorm normalized name: SB-649868
DrugBank: SB-649868 (DB14822)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradiscal injection
Trial: NCT05516992
Drug: Sham Needle
RxNorm normalized name: NEEDLE
DrugBank: Pine needle oil (pinus mugo) (DB11276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham needle placement
Trial: NCT06426108
Drug: Fluoride Varnishes
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the investigators will utilize a fluoride varnish with a concentration of 22,600 ppm F. The application will be facilitated using a microbrush, ensuring thorough coverage over the entire length of the lesion for a duration of 30 seconds. Following application, the varnish will be finished with water to create a film on the tooth surface. After completing the interventions, patients will receive instructions to refrain from consuming hard foods and to postpone tooth brushing for at least four hours, adhering to the manufacturer's recommendations.
Trial: NCT05147233
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone
Trial: NCT05532059
Drug: gemcitabine and cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: gemcitabine and cisplatin
Trial: NCT05289167
Drug: Abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose level 0: 10 mg/kg IV over 30 minutes on day +5~Dose level 1: 10mg/kg IV over 30 minutes on day +5 and +14~Dose level 2: 10mg/kg IV over 30 minutes on day +5, +14, and +28
Trial: NCT05289167
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1.3 mg/m2 IV 6 hours after graft infusion completion and 72 hours thereafter.
Trial: NCT05548452
Drug: Intestinal Microbiota Transplant (IMT) Capsules
RxNorm normalized name: Washed Microbiota Transplantation
DrugBank: Washed Microbiota Transplantation (DB15745)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules containing freeze-dried intestinal microbiota from healthy human donors
Trial: NCT06297629
Drug: Donor Lymphocyte Infusion
RxNorm normalized name: Therapeutic allogeneic lymphocytes
DrugBank: Therapeutic allogeneic lymphocytes (DB17459)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by Infusion
Trial: NCT06720298
Drug: 18F-FDG
RxNorm normalized name: 18F-FDG
DrugBank: Fludeoxyglucose (18F) (DB09502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All study participants will undergo one 18F-FDG PET/ CT scan.
Trial: NCT05777902
Drug: Ozanimod Oral Capsule
RxNorm normalized name: ozanimod Oral Capsule
DrugBank: Ozanimod (DB12612)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: We propose to integrate measurements obtained using multiple tools. Patients will undergo MRI and hdEEG procedures, and blood samples will be obtained for the immunological and biochemical studies on the same day. The study of the immune system's status will include an extensive immunophenotypic analysis, a functional characterization following ex vivo stimulation of innate immune cells, and the measurement of soluble products in the serum, such as cytokines. Cellular traits of interest include the absolute numbers and relative proportions of specific cell subsets, transcriptional states, secretory functions, proliferative capacity or cytolytic potential. Specifically, the following antibody combination will constitute the core of the immunophenotypic analysis: HLADR CD11c, CD38, CD14, CD123, lineage (CD3, CD56, CD19).
Trial: NCT06358755
Drug: Low dose atropine
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.01% atropine administrated twice per day (1 drop in the morning and 1 drop at night before bedtime) will be given as intervention.
Trial: NCT04668885
Drug: CPX-351
RxNorm normalized name: CPX
DrugBank: DPCPX (DB12946)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction phase: CPX-351 15 mg/m\^2 on days 1 and 3 of each 28-day cycle for up to a total of 6 cycles in the absence of unacceptable toxicity~Maintenance phase: CPX-351 7.5 mg/m\^2 on days 1 and 3 for two cycles alternating with 15 mg/m\^2 for one cycle. Participants may receive up to 12 cycles of maintenance phase in the absence of unacceptable toxicity.
Trial: NCT04727970
Drug: Tricaprilin
RxNorm normalized name: TRICAPRILIN
DrugBank: Tricaprylin (DB12176)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tricaprilin will be emulsified in infant formula/milk
Trial: NCT06103825
Drug: Solriamfetol
RxNorm normalized name: Solriamfetol
DrugBank: Solriamfetol (DB14754)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: solriamfetol : QD，PO，Day 1-Day 84；
Trial: NCT06705725
Drug: CBG002 CAR-T Cell Suspension
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of CAR+ T cells will be infused, and classic 3+3 dose escalation will be applied.
Trial: NCT05324358
Drug: Ketorolac Tromethamine
RxNorm normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketorolac tromethamine, alcohol free formulation, 1.0 mg/mL in saline solution (\~0.9% NaCl) adjusted to a pH of \~7.4. Contained in a sterile, 200 mL polyolefin bag (filled with 125 mL of NTM-001).
Trial: NCT05324358
Drug: Morphine Sulfate
RxNorm normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine single use vials at 4 mg/mL, filled with 1 mL.
Trial: NCT05646563
Drug: Soliris
RxNorm normalized name: Soliris
DrugBank: Eculizumab (DB01257)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Complement C5 blocker administered intravenously
Trial: NCT05297240
Drug: Belantamab mafodotin
RxNorm normalized name: belantamab mafodotin
DrugBank: Belantamab mafodotin (DB15719)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: At least one dose of belantamab mafodotin as part of the compassionate use or the expanded access program in Spain between November 2019 and June 2021.
Trial: NCT04925375
Drug: Abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Abatacept is a selective costimulation modulator, inhibiting T lymphocyte activation by binding to CD80 and CD86, thereby blocking interaction with CD28. Orencia solution supplied in a prefilled syringe should be refrigerated at 2C to 8C (36F to 46F). Orencia should not be used beyond the expiration date on the prefilled syringe. The product should be protected from light by storing in the original package until time of use. The prefilled syringe should not be frozen.
Trial: NCT06340685
Drug: Triheptanoin
RxNorm normalized name: Triheptanoin
DrugBank: Triheptanoin (DB11677)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Open-label design with doses of triheptanoin up to 4.0 gm/kg triheptanoin
Trial: NCT04971980
Drug: hUC-MSC infusion (BC-U001)
RxNorm normalized name: Duo Fusion
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The participants are intravenously administered a single infusion of hUC-MSC at 0.5x10\^6 cells/kg body weight, 1.0x10\^6 cells/kg body weight, 1.5x10\^6 cells/kg body weight for low-dose cohort, medium-dose cohort and high-dose cohort respectively.
Trial: NCT05895786
Drug: PF-06823859
RxNorm normalized name: Immunoglobulin G1 [236-alanine,237-alanine,239-alanine,de-C-terminal-lysine], anti-(human interferon β) (human-Mus musculus monoclonal PF-06823859 γ1-chain), disulfide with human-Mus musculus monoclonal PF-06823859 κ-chain, dimer
DrugBank: Dazukibart (DB18429)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-interferon beta therapy
Trial: NCT06191965
Drug: MitoQ
RxNorm normalized name: Mitoquinone
DrugBank: Mitoquinone (DB05063)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MitoQ is a synthetic analogue of coenzyme Q10. It is produced by the company Antipodean Pharmaceuticals and is formulated as a stable yellow powder suitable for oral formulation, prepared as capsules of white color. It is a commercial dietary supplement sold over the counter as an antioxidant, to be taken orally once or twice a day. It has subsequently been tested for various clinical conditions in humans.~1. Molecular formula: C38H47O7PS (C37H44O4P.CH3O3S)~2. CAS number: 444890-41-9 (phosphonium cation)~3. Molecular weight: 678.81~4. MitoQ capsules: The standard commercial posology is a 20 mg daily dose. All formulations are produced following Good Manufacturing Practice (GMP) standards (https://www.who.int/medicines/areas/quality_safety/quality_assurance/TRS986annex2.pdf?ua=1).~5. MitoQ will be administered in oral capsules provided by the manufacturer Antipodean Pharma, to be taken once daily, one hour before breakfast. The daily dose will be 2 pills, i.e., 40 mg MitoQ.
Trial: NCT06003231
Drug: disitamab vedotin
RxNorm normalized name: Disitamab vedotin
DrugBank: Disitamab vedotin (DB17208)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given into the vein (IV, intravenous) every 2 weeks
Trial: NCT05109364
Drug: Terazosin therapy
DrugBank: Terazosin (DB01162)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Primary procedures in this study are MIBG scan, DAT scan, NM-MRI, and terazosin titration. Subjects will return for research visits and imaging every six months for three years. The investigators hypothesize that the rate of decline in DAT scan123I-Ioflupane uptake will be slower in subjects who have received the a1- Adrenergic Receptor Antagonist Terazosin, resulting in a decreased clinical conversion rate to parkinsonism.
Trial: NCT04821622
Drug: talazoparib plus enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: experimental arm
Trial: NCT04821622
Drug: Placebo plus enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Active comparator arm
Trial: NCT05423106
Drug: JNJ-64457744
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-64457744 will be administered as oral solution.
Trial: NCT05423106
Drug: Tenofovir Disoproxil Fumarate (TDF)
RxNorm normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TDF tablet will be administered orally
Trial: NCT05423106
Drug: Tenofovir Alafenamide (TAF)
DrugBank: Tenofovir alafenamide (DB09299)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: TAF tablet will be administered orally.
Trial: NCT05423106
Drug: Entecavir (ETV)
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ETV tablet will be administered orally.
Trial: NCT05423106
Drug: JNJ-64457744
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-64457744 will be administered as oral tablet.
Trial: NCT04305158
Drug: Nitrous Oxide
RxNorm normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient receiving nitrous oxide are evaluated for success of the procedure
Trial: NCT04963738
Drug: JNJ-73763989
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-73763989 will be administered as a single SC injection.
Trial: NCT05379803
Drug: Furmonertinib
RxNorm normalized name: Almonertinib
DrugBank: Almonertinib (DB16640)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: furmonertinib 160 mg orally QD
Trial: NCT05076981
Drug: human chorionic gonadotropin
RxNorm normalized name: human chorionic gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once the dominant follicle reaches 17mm or above, a bolus of 6500 rhCG (Ovitrelle, Merck-Serono) will be administered subcutaneously
Trial: NCT04659044
Drug: Polatuzumab Vedotin
RxNorm normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT04659044
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT06297083
Drug: Peanut Oral Powder [PEANUT POWDER]
RxNorm normalized name: Peanut Oral Powder [PEANUT POWDER]
DrugBank: Peanut (DB10553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peanut oral immunotherapy at varying doses and build-up regimes given daily for 18 months
Trial: NCT05518812
Drug: Carboprost Tromethamine
RxNorm normalized name: Carboprost Tromethamine
DrugBank: Carboprost tromethamine (DB00429)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During myomectomy, low-dose carboprost will be injected at the base of the fibroid and repeated as necessary. The efficacy of low-dose carboprost is being assessed, and the total dose administered will not exceed single vial for other indications.
Trial: NCT05158244
Drug: PF-07081532
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study Drug, once daily for 42 days
Trial: NCT02307812
Drug: Ramucirumab
RxNorm normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered intravenously (IV)
Trial: NCT02307812
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered IV
Trial: NCT04825574
Drug: Avapritinib
RxNorm normalized name: Avapritinib
DrugBank: Avapritinib (DB15233)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: avapritinib tablet
Trial: NCT06595979
Drug: Polymyxin B
RxNorm normalized name: Polymyxin B
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants in this group will receive polymyxin B administered directly into the brain (intracranial administration) without intravenous (IV) infusion.
Trial: NCT06598735
Drug: HRS-4508
RxNorm normalized name: HRS-1167
DrugBank: HRS-1167 (DB18703)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRS-4508
Trial: NCT06651749
Drug: Propofol injection
RxNorm normalized name: propofol Injection
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: hemodynamic changes of a high dose versus low dose propofol during induction of anesthesia.